Curameda - Company finances
|
EUR
|
2020
From: 2020-05-27
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 2,821 | 25,653 | 23,838 | 22,717 | 45,410 | 87,715 |
| Profit before tax | 393 | 1,302 | 1,058 | 615 | 17,797 | 11,092 |
| Net profit | 393 | 1,237 | 1,005 | 584 | 16,907 | 10,441 |
| Equity | 1,393 | 2,630 | 3,635 | 4,218 | 21,125 | 31,566 |
| Liabilities | 1,146 | 2,039 | 0 | 11,095 | 15,381 | 10,860 |
| Non-current assets | 0 | 0 | 0 | 0 | 1,264 | 2,570 |
| Current assets | 2,539 | 4,669 | 2,809 | 13,185 | 35,242 | 39,856 |
| Total assets | 2,539 | 4,669 | 2,809 | 13,185 | 36,506 | 42,426 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 1,930 | 6,476 | 17,754 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | +809.4% | -7.1% | -4.7% | +99.9% | +93.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 15.5% | 26.5% | 35.8% | 4.4% | 46.3% | 24.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 28.2% | 47.0% | 27.6% | 13.8% | 80.0% | 33.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 13.9% | 4.8% | 4.2% | 2.6% | 37.2% | 11.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 13.9% | 5.1% | 4.4% | 2.7% | 39.2% | 12.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.8 | 0.8 | - | 2.6 | 0.7 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Curameda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-03 | 2026-02-28 | 8.03 |
Curameda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-10-02 | 2024-10-16 | 0.08 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Curameda, MB (code 305558827) is a small partnership engaged in the retail sale of other medical and orthopaedic goods. In 2025, the company generated revenue of €87.7K and net profit of €10.4K, with a profit margin of 11.9%. Revenue rose by 93.2% year on year and by 286.1% over two years, reflecting a strong expansion from €22.7K in 2023 to €45.4K in 2024 and then to the latest level. Profitability was more volatile, as net profit increased from €584 in 2023 to €16.9K in 2024 before easing in 2025, while remaining clearly positive. Profit before tax amounted to €11.1K in 2025.
The balance sheet also strengthened in 2025. Total assets reached €42.4K, equity €31.6K and liabilities €10.9K. Equity represented 74.4% of assets, debt-to-equity was 0.34, and asset turnover stood at 2.07x. Compared with 2024, the company expanded its asset base and equity while liabilities declined, indicating a stronger financial position.
The balance sheet also strengthened in 2025. Total assets reached €42.4K, equity €31.6K and liabilities €10.9K. Equity represented 74.4% of assets, debt-to-equity was 0.34, and asset turnover stood at 2.07x. Compared with 2024, the company expanded its asset base and equity while liabilities declined, indicating a stronger financial position.